The Mechanism and Therapeutic Targeting of Interleukin-1β in Heart Failure
VCU Scholars Compass (Virginia Commonwealth University) · 01.01.2023
DOI: 10.25772/gfkx-1133 ↗Kurz gefasst
Fachartikel in der Zeitschrift VCU Scholars Compass (Virginia Commonwealth University), erschienen am 01.01.2023. Verfasst von Pratyush Narayan.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Heart failure (HF) is a clinical syndrome caused by impaired cardiac function accompanied by symptoms of dyspnea, fatigue, congestion, and exercise intolerance. HF remains a leading cause of hospitalization and mortality in the United States and worldwide, and its prevalence continues to increase. A chronic and low-grade state of inflammation is a key factor in the pathophysiology of HF development and acute decompensation in patients with HF. Interleukin-1 is a prototypal, pro-inflammatory cytokine implicated in HF and as a reversible negative modulator of cardiac contractility. In healthy adult mice, administering a single dose of recombinant-mouse IL-1β (IL-1β) precipitates acute systolic dysfunction. The systolic dysfunction peaks 4 hours after administration and resolves after 24 hours. The transient nature of IL-1-induced cardiac dysfunction is noteworthy for HF treatment. Nonetheless, the blockade of IL-1, as with many other immunomodulatory treatment approaches, may increase the risk of infection and infection-related complications and inadvertently block the protective effects of IL-1-mediated inflammation. Therefore, understanding the mechanism of IL-1 induced cardiac dysfunction may uncover promising targeted therapeutics for the treatment of HF, while avoiding the negative effects of whole IL-1 blockade, with the goal of increasing quality of life as well as decreasing cardiovascular and all-cause mortality in HF patients. Phosphoinositide 3-kinase gamma (PI3K p110γ) has been implicated in myocardial contractile depression through the involvement of phosphodiesterase 3 (PDE3), and a novel unconventional IL-1 receptor signaling pathway through PI3K p110γ has been described in inflammation and cancer. Whether the cardiac modulatory effects of IL-1 are mediated through PI3K p110γ is not known. Furthermore, IL-1 is increased in acute myocardial infarction and HF, and has been shown to promote adverse remodeling in both. Blockade of IL-1 has shown promise in several clinical trials as safe and with the potential to decrease hospitalization and improve exercise performance in HF patients. However, the direct role of IL-1 on exercise tolerance is unknown, and the effect of IL-1 blockade on exercise tolerance in acute myocardial infarction and ischemic HF has not been studied in preclinical models. Likewise, IL-1 activity is implicated in aging-associated inflammation (inflamm-aging), and IL-1 may be a modulator of metabolic and structural changes causing aging-associated cardiomyopathy. Herein, we conducted three major studies in murine models to further understand IL-1 mediated cardiac effects. 1.) We tested whether IL-1 signaling,in vitro and in vivo, is mediated through the PI3K p110γ serine/threonine protein kinase scaffolding function linked to PDE3 in an effort to elucidate the mechanism by which IL-1 induces cardio-depression in the mouse. 2.) In a translational relevant study, we evaluated the effect of IL-1 blockade with Anakinra, a human recombinant IL-1 receptor antagonist (IL-1Ra), on exercise tolerance in non-reperfused acute myocardial infarction (AMI), as well as in a model of HF in the mouse. 3.) Using a murine model of genetically knocked out IL-1 receptor I (IL-1RI), the receptor through which IL-1 signals, we assessed the role of IL-1 in aging-associated cardiomyopathy.
Results
IL-1 induces both PI3K p110γ mRNA and protein in IL-1 treated in vivo murine whole heart tissue and in IL-1 treated murine primary cardiomyocytes in culture. The lack of PI3K p110γ (p110γKO) confers resistance to IL-1-induced systolic dysfunction, although this was not true in mice who had catalytically inactive/kinase dead PI3K p110γ (p110γΚD). The administration of Milrinone (PDE3 inhibitor) fully restored systolic function in the setting of IL-1-induced systolic dysfunction. In addition, the administration of IL-1β to mice promoted exercise intolerance. The blockade of IL-1 with Anakinra counteracted exercise intolerance after non-reperfused acute myocardial infarction (AMI) in mice. Anakinra also rescued cardiac contractile reserve and exercise tolerance in a murine model of ischemic HF. Finally, the deletion of IL-1 receptor type I (IL-1RIKO) in mice prevented the development of aging-associated cardiomyopathy and HF phenotype in aging mice by preventing aging-associated left ventricular hypertrophy, diastolic dysfunction, and the increase in end-diastolic pressure and myocardial interstitial fibrosis.
Conclusion
Our findings implicate IL-1 signaling as a key cardio-depressant in HF and the blockade of IL-1 or its downstream effectors hold promise for treating HF. Therefore, our results encourage further study of IL-1 in heart failure.
Schlagwörter
Zitieren
APA
Narayan, P. (2023). The Mechanism and Therapeutic Targeting of Interleukin-1β in Heart Failure. VCU Scholars Compass (Virginia Commonwealth University). https://doi.org/10.25772/gfkx-1133
Vancouver
Narayan P. The Mechanism and Therapeutic Targeting of Interleukin-1β in Heart Failure. VCU Scholars Compass (Virginia Commonwealth University). 2023. doi:10.25772/gfkx-1133
BibTeX
@article{Narayan2023,
author = {Narayan, Pratyush},
title = {The Mechanism and Therapeutic Targeting of Interleukin-1β in Heart Failure},
journal = {VCU Scholars Compass (Virginia Commonwealth University)},
year = {2023},
doi = {10.25772/gfkx-1133}
}
EUVIMED